Zacks Research Lifts Earnings Estimates for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Zacks Research lifted their Q1 2027 earnings per share (EPS) estimates for shares of Gilead Sciences in a report released on Tuesday, September 1st. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $2.09 for the quarter, up from their previous estimate of $2.08. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.47) per share. Zacks Research also issued estimates for Gilead Sciences’ Q2 2027 earnings at $2.24 EPS, Q3 2027 earnings at $2.43 EPS, Q4 2027 earnings at $2.60 EPS and FY2027 earnings at $9.36 EPS.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.01 EPS.

A number of other research analysts have also weighed in on GILD. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Weiss Ratings lowered Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Truist Financial reduced their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Rothschild & Co Redburn reduced their price target on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Finally, HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $133.00 to $155.00 in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $149.92 on Wednesday. The firm’s 50 day moving average is $135.17 and its 200 day moving average is $136.46. The stock has a market capitalization of $185.89 billion, a P/E ratio of -56.15 and a beta of 0.33. Gilead Sciences has a 12 month low of $108.46 and a 12 month high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the transaction, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. The trade was a 58.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 90,000 shares of company stock valued at $12,266,220 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $25,000. Persistent Asset Partners Ltd bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $25,000. Kimelman & Baird LLC purchased a new stake in Gilead Sciences in the second quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC grew its position in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Finally, Quattro Advisors LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth approximately $26,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA approval expands HIV portfolio: The FDA approved Bixlenvo, Gilead’s once-daily, single-tablet regimen for virologically suppressed adults with HIV. The treatment could broaden Gilead’s offerings, particularly among underserved patients, and create an additional source of HIV revenue. FDA Approves Gilead’s New Single Tablet HIV Regimen
• Positive Sentiment: Strong Buy ranking reinforces earnings optimism: Zacks upgraded Gilead to a Rank #1, or Strong Buy, citing improving earnings prospects. The upgrade may attract additional investor interest. Gilead Upgraded to Strong Buy
• Positive Sentiment: 2027 earnings estimates moved higher: Zacks raised its forecasts for every quarter in 2027 by $0.01 to $0.02 per share and increased its full-year estimate to $9.36 from $9.30. Erste Group also lifted its FY2027 estimate to $9.86 from $9.57. Although the revisions are modest, they indicate improving analyst expectations for Gilead’s earnings trajectory.
• Neutral Sentiment: Analyst support comes with limitations: Wall Street’s average recommendation remains favorable, but the accompanying analysis notes that sell-side ratings can be overly optimistic and may have limited predictive value. Investors will likely look for evidence that Bixlenvo gains meaningful market adoption.
• Neutral Sentiment: Stock near the upper end of its range: GILD is trading well above its 50-day and 200-day moving averages and close to its 52-week high, suggesting that considerable optimism may already be reflected in the valuation. This could limit near-term upside if product launches or earnings fail to exceed expectations.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.